You-Xin Chen, Yu-Qing Zhang, Chang-Zheng Chen, Hong Dai, Su-Yan Li, Xiang Ma, Xiao-Dong Sun, Shi-Bo Tang, Yu-Sheng Wang, Wen-Bin Wei, Feng Wen, Ge-Zhi Xu, Wei-Hong Yu, Mei-Xia Zhang, Ming-Wei Zhao, Yang Zhang, Fang Qi, Xun Xu, Xiao-Xin Li
Background In mainland China, patients with neovascular age-related macular degeneration (nAMD) have an approximately 40% prevalence of polypoidal choroidal vasculopathy (PCV). This disease leads to polys, recurrent retinal pigment epithelium detachment (PED), extensive subretinal or vitreous hemorrhages, and severe vision loss. China has introduced various treatment modalities in the past years, and gaining comprehensive experience in treating PCV is necessary. Methods A total of 14 retinal specialists nationwide with expertise in PCV were empaneled to prioritize six questions and address their corresponding outcomes, regarding opinions on inactive PCV, choices of anti-vascular endothelial growth factor (anti-VEGF) monotherapy, photodynamic therapy (PDT) monotherapy or combined therapy, patients with persistent subretinal fluid (SRF) or intraretinal fluid (IRF) after loading dose anti-VEGF, or patients with massive subretinal hemorrhage...
May 31, 2023: Chinese Medical Sciences Journal